



#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: STAM et al.

SERIAL NO.: 10/527,571

FILING DATE: 14 March 2005

TITLE: NUCLEIC ACID SEQUENCES
FROM DROSOPHILA MELANOGASTER
THAT ENCODE PROTEINS ESSENTIAL
FOR VIABILITY AND USES THEREOF

ATTORNEY DOCKET NO.: 70131USPCT

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR §1.56, Applicants wish to call the Examiner's attention to the references cited on the attached Form PTO-1449. The items listed on the enclosed Form PTO-1449 may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application.

Copies of all cited references are enclosed herewith.

The submission of these references is made solely for the purpose of complying with Applicant's duty of disclosure, and is not intended as a surrender of patentable subject matter nor is it intended to create prosecution history estoppel.

A copy of the International Search Report is also enclosed.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

The Examiner is requested to consider the foregoing information in relation to this application and to indicate that each reference was considered by returning a copy of the initialed PTO 1449 forms.

In accordance with 37 CFR §1.97(b)(3), no fee is believed to be required for consideration of this statement because it is being submitted before the mailing date of a first Office Action on the merits. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 50-1744 of Syngenta Biotechnology Inc.

Respectfully submitted,

Mary Kakefuda
Mary Kakefuda
Attorney for Applicant
Registration No 39,245

Syngenta Biotechnology, Inc.
3054 Cornwallis Road
Research Triangle Park, NC 27709-2257
Telephone: 919-765-5071

Date: *June 20, 2005*



Attorney Docket No.: 70131USPCT
Serial No.: 10/527,571

FILING BY "FIRST CLASS MAIL" UNDER 37 C.F.R. § 1.8

I hereby certify that the following correspondence is being deposited with the United States Postal Service as "First Class Mail" with proper postage in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313, on June 20, 2005.

- 1) Information Disclosure Statement
- 2) FORM PTO-1449 – Information Disclosure Citation
- 3) Copy of the International Search Report for International Application No. PCT/US2003/024982
- 4) Reference AA, AB, and AD
- 5) Return Postcard

Melissa Hardy
Name

Melissa Hardy
Signature

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

JUN 22 2005

PATENT & TRADEMARK OFFICE 880

Sheet 1 of 1

ATTY. DOCKET NO.
70131USPC
APPLICATION NO.
10/527,571
APPLICANT
STAM et al.
FILING DATE:
14 March 2005

Confirmation No.

Group Art Unit:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	US-2002-0160934-A1	10/31/2002	Broadus et al.	514	1	03/27/2002
	AB	6,703,491	03/09/2004	Homburger et al.	536	23.1	03/17/1999

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES <input type="checkbox"/> NO <input type="checkbox"/>
	AC						<input type="checkbox"/> <input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AD	Towers, et al., <i>A Drosophila Melanogaster Cell Line (S2) Facilitates Post-Genome Functional Analysis of Receptors and Ion Channels</i> . BioEssays. 2002, Vol. 24, No. 11, 1066-1073.
AD	
AE	
AF	
AG	
AH	
AI	
AJ	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.